Revvity 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Revvity reported Q3 2026 revenue of $710 million, with 7% pro forma organic growth; foreign exchange was an approximate 1% headwind to growth, while ACD Labs contributed approximately 1%.
- Pro forma adjusted operating margin was 29.4%, approximately 40 basis points ahead of expectations, and pro forma adjusted earnings per share was $1.37, up 21% year over year and $0.08 above the midpoint of expectations.
- Free cash flow was $152 million, equal to 99% conversion of adjusted net income; year-to-date free cash flow exceeded $450 million, with a 105% conversion rate.
- Life Sciences revenue was $380 million, up 11% reported and 9% organically. Signals software grew in the high teens organically, reagents grew in the high single digits, and instruments grew in the mid single digits.
- Diagnostics revenue was $330 million, up 4% reported and 5% organically. Immunodiagnostics grew in the high single digits organically, while reproductive health grew in the low single digits.
- Europe continued double-digit growth for the fourth consecutive quarter, and the Americas also grew double digits. APAC had a low single-digit decline, as reproductive health pressures offset double-digit Life Sciences growth in China.
- The company ended the quarter with net debt to adjusted EBITDA leverage of 2.3 times. Its long-term debt was 100% fixed rate, with a weighted average interest rate of 2.8% and a weighted average maturity of seven years.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for joining us, and welcome to the Q3 2026 Revvity Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Steve Willoughby, Senior Vice President, Investor Relations. Steve, please go ahead. Thank you, operator.
Good morning, everyone, and welcome to Revvity's third quarter 2026 earnings conference call. On the call with me today are Prahlad Singh, our President and Chief Executive Officer, and Max Krakowiak, our Senior Vice President and Chief Financial Officer. Before we begin, I'd like to remind you that today's call may include forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from our expectations. Please refer to the safe harbor statements in our earnings release and to our SEC filings for a detailed discussion of these risk factors. We assume no obligation to update these forward-looking statements in the future. Additionally, we will refer to certain non-GAAP financial measures during this call. Reconciliations to the most directly comparable GAAP measures are available in our earnings release. I'll now turn it over to our President and Chief Executive Officer, Prahlad Singh.
Prahlad? Thank you, Steve, and good morning, everyone.
I'm pleased to report that Revvity delivered exceptionally strong performance in the third quarter, with pro forma organic growth of 7%, exceeding our mid-single-digit expectation. With healthy gross margins, combined with sales leverage from the revenue upside we experienced, our strong incremental margins shine through, leading to pro forma adjusted operating margins in the quarter of 29.4%. This resulted in pro forma adjusted earnings per share of $1.37 for the quarter, which was $0.08 above the midpoint of our expectations. Our stronger-than-expected performance in the quarter was driven by our life sciences segment, which grew 9% organically, with reagents up high single digits, instruments up strong mid-single digits, and our Signals Software business growing in the upper teens. This fantastic performance was complemented by solid performance in our diagnostics segment, which grew in the mid-single digits, in line with our expectations.
As we have been sharing with you for the last several quarters, underlying market demand trends from our pharma and biotech customers continued to improve in the third quarter, following the policy-related headwinds our industry faced throughout much of last year. On top of this market recovery, we also continued to see incremental AI-related demand build and begin to expand beyond just a high-content screening business, where it has initially been concentrated. While our high-content screening revenue growth continued to accelerate in the quarter, despite strong year-ago comps, our backlog for these instruments also continued to increase. We have taken additional actions to further expand our capacity in this area to support this elevated demand, while also building some additional capacity should it accelerate even more as we head into next year.
I think the most important dynamic we saw in the third quarter was that the end market improvements and AI-related incremental demand we have experienced over the past few quarters began to positively impact other parts of our portfolio beyond just our cellular analysis franchise. For example, as I have mentioned, our life sciences reagents grew in the high single digits in the quarter, which was its strongest performance in several years across both pharma biotech and academia and government. Our reagent performance in the quarter also benefited from execution of our bulk orders backlog getting fulfilled, along with an improvement in our run rate business as well. We also saw other pieces of our instruments portfolio improve, such as our detection franchise, primarily consisting of our high-throughput screening instruments, which incurred solid growth in the quarter with improving momentum as we head into year-end.
Overall, the market continues to remain dynamic, but is moving in the right direction. AI-related demand is beginning to be seen across a wider cross-section of our offerings, but it is still in its very early days. I feel our customers are only beginning to scratch the surface in how AI is reshaping their workflows and how preclinical science is conducted. One thing I find particularly interesting is the amount of scientific data that can now actually be used. Our reagents and instruments have been generating large amounts of biological data for years. What has changed is the ability to now combine that information with other data sets and extract additional insights from it much faster than was previously possible. As customers look to build larger biological datasets to train and refine their AI models, they are going to need exponentially more data from the wet lab.
Our life sciences portfolio is well-positioned to help them generate, analyze, and validate that data. I am looking forward to our Investor Day taking place next Friday, November 13, where we will spend more time discussing how we see science and R&D changing because of AI, and why Revvity is well-positioned to support our customers through these changes. I hope many of you will be able to join us either in person or virtually. Another aspect of how the scientific world is changing because of AI that we plan to spend time on at our Investor Day is within our Signals Software business. As expected, this business delivered strong performance in the third quarter, and as we have highlighted throughout this year, 2026 will be the most significant year of new product launches in its history.
Just two weeks ago, we announced the launch of Signals LabGistics, a novel AI-native offering that helps connect and coordinate scientific workflows across different people, systems, and stages of development. Today, a lot of that work can still be fragmented, particularly as a drug moves from discovery into development and ultimately into manufacturing. LabGistics is designed to bring those different pieces together, which we believe can help our customers work more efficiently and ultimately move promising therapies forward faster. The launch of LabGistics caps an exciting year for Signals, where we have also introduced Xynthetica, BioDesign, Signals AI, and our Anthropic connector. Some of these offerings were not even on the drawing board 12 to 18 months ago, which says a lot about the team's ability to respond as technology and our customers' needs change.
I'm excited about how the business is positioned for what comes next and look forward to further showcasing our Signals franchise next week. During the quarter, we also demonstrated our continued innovation in our diagnostics segment by recently launching in Europe our new CE-IVDR-certified GSP T1D 3plex kit for the early detection of type 1 diabetes. This is an important innovation for us because it capitalizes on the capabilities and infrastructure we've built over many years in newborn screening and extends our expertise into early childhood screening, which is a new market for us. Using a simple dried blood spot sample on our existing GSP platform, the new test can screen children at risk for type 1 diabetes months or even years before symptoms appear, creating the opportunity for earlier intervention.
Given the increasing incidence of type 1 diabetes and the growing interest in population-level screening, we think this is a great example of how we can leverage our existing instrument installed base, scientific expertise, workflows, and customer relationships to expand into important new areas of diagnostics which have significant unmet needs. I'm optimistic about the potential of this new 3-Plex assay as adoption expands, initially across European countries. At the same time, we are advancing the development in our pipeline of an even broader T1D assay in collaboration with Sanofi. Over the last few months, I've spent time at a number of our sites around the world, including our operations in Lübeck and Hamburg, Germany, as well as our newly modernized campus in Hopkinton, Massachusetts. These visits give me a valuable opportunity to see firsthand the progress our teams are making.
Every one of these sites is running better than it was two years ago, and the teams are motivated and engaged to do even more. Hopkinton is a good example. We've consolidated key life sciences and diagnostics activities onto one campus there, including R&D and manufacturing. That's part of the increased efficiency we've talked about over the past several quarters. It simplifies our footprint and increases our team's opportunities to collaborate. I look forward to having you visit this updated campus outside of Boston in the future. We are seeing similar progress with the efficiency of our diagnostics work in Europe, as we've mentioned over the last year. These actions are now starting to show up in our numbers, as adjusted operating margins for our diagnostics segment in 3Q were 29.9%, which included 160 basis points of headwind from our immunodiagnostics business in China that we are working to divest.
Excluding this business in China, our diagnostics margins were up over 600 basis points year-over-year, and over 30% overall in the quarter. These efforts, which I was able to view firsthand over the last few months, are helping to allow Revvity's full potential to shine through. Our 40% plus incremental margins were on full display in the quarter, which I expect will continue going forward. We are in a good position to deliver a strong finish to 2026, with solid momentum heading into next year. While Max will provide more details in a moment, given the improving performance we've seen over the first nine months of the year, and our expectation for current underlying market trends to continue during the fourth quarter, we now expect our full year pro forma organic growth to be approximately 5%.
Considering we started the year with a 2%-3% organic growth outlook, it is clear that our performance this year has been progressively moving in the right direction. Given our earnings outperformance in the third quarter, we now expect our pro forma adjusted EPS for the full year to be in the range of $5.40-$5.45, which equates to approximately 12% growth year-over-year. In closing, we have driven strong levels of operational, commercial, and financial execution over the last several years since becoming Revvity, while overcoming what have been fairly challenging end market environments that we have been able to consistently outperform by several hundred basis points. I believe our third quarter performance fully demonstrated for the first time since the start of our recent transformation what our true potential is as a company.
Our specialty offerings across life sciences and diagnostics are seeing stronger and differentiated levels of demand due to their robust innovation and our ability to deliver the solutions that our customers need. Our significant operational efforts are having a meaningful impact, which should continue to benefit us as we move forward. With AI-related demand tailwinds beginning to come into view, Revvity is well-positioned to capitalize on these emerging opportunities and help power scientific innovation alongside our customers. Finally, I look forward to seeing many of you next week at our Investor Day in New York. With that, I will turn the call over to Max.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
